首页> 美国卫生研究院文献>Bioscience Reports >SH003 reverses drug resistance by blocking signal transducer and activator of transcription 3 (STAT3) signaling in breast cancer cells
【2h】

SH003 reverses drug resistance by blocking signal transducer and activator of transcription 3 (STAT3) signaling in breast cancer cells

机译:SH003通过阻断乳腺癌细胞中的信号转导和转录激活因子3(STAT3)信号来逆转耐药性

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Overcoming drug resistance is an important task for investigators and clinician to achieve successful chemotherapy in cancer patients. Drug resistance is caused by various factors, including the overexpression of P-glycoprotein (P-gp, MDR1). The development of new, useful compounds that overcome drug resistance is urgent. SH003 is extracted from the mixture of three different herbs, and its anticancer effect has been revealed in different cancer cell types. In the present study, we investigated whether SH003 is able to reverse drug resistance using paclitaxel-resistant breast cancer cells (MCF-7/PAC). In our experiments, SH003 significantly decreased cell growth and colony formation in MCF-7/PAC cells and parental MCF-7 cells. This growth inhibition was related to the accumulation of cells in the sub-G0/G1 apoptotic population and an increase in the number of apoptotic cells. SH003 reduced the mRNA expression of multidrug resistance 1 (MDR1) and multidrug resistance-associated proteins (MRPs) in MCF-7/PAC cells. SH003 also down-regulated the expression of P-gp. SH003 reversed drug efflux from MCF-7/PAC cells, resulting in rhodamine123 (Rho123) accumulation. Inhibition of drug resistance by SH003 is related to the suppression of the signal transducer and activator of transcription 3 (STAT3) signaling pathway. SH003 decreased STAT3 activation (p-STAT3) and its nuclear translocation and inhibited the secretion of VEGF and MMP-2, which are STAT3 target genes. An STAT3 inhibitor, JAK inhibitor I and an HIF-1α inhibitor decreased cell growth in MCF-7 and MCF-7/PAC cells. Taken together, these results demonstrate that SH003 can overcome drug resistance, and SH003 might be helpful for chemotherapy in cancer patients.
机译:克服耐药性是研究人员和临床医生在癌症患者中成功实现化疗的重要任务。耐药性是由多种因素引起的,包括P-糖蛋白(P-gp,MDR1)的过度表达。克服药物耐药性的新的有用化合物的开发迫在眉睫。 SH003是从三种不同草药的混合物中提取的,其抗癌作用已在不同类型的癌细胞中显示出来。在本研究中,我们调查了SH003是否能够使用耐紫杉醇的乳腺癌细胞(MCF-7 / PAC)逆转耐药性。在我们的实验中,SH003显着降低了MCF-7 / PAC细胞和亲代MCF-7细胞的细胞生长和集落形成。这种生长抑制与亚G0 / G1细胞凋亡群体中细胞的积累和细胞凋亡数量的增加有关。 SH003降低了MCF-7 / PAC细胞中多药耐药性1(MDR1)和多药耐药性相关蛋白(MRP)的mRNA表达。 SH003也下调了P-gp的表达。 SH003逆转了MCF-7 / PAC细胞的药物外排,导致罗丹明123(Rho123)积累。 SH003对耐药性的抑制作用与信号转导子和转录激活因子3(STAT3)信号通路的抑制有关。 SH003降低STAT3激活(p-STAT3)及其核易位,并抑制STAT3靶基因VEGF和MMP-2的分泌。 STAT3抑制剂,JAK抑制剂I和HIF-1α抑制剂可降低MCF-7和MCF-7 / PAC细胞的细胞生长。综上所述,这些结果表明SH003可以克服耐药性,并且SH003可能有助于癌症患者的化学疗法。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号